國家衛生研究院 NHRI:Item 3990099045/14572

NHRI > Institute of Biotechnology and Pharmaceutical Research > Kak-Shan Shia > Periodical Articles > Item 3990099045/14572

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14572

Title:	Protective effect of CXCR4 antagonist DBPR807 against ischemia-reperfusion injury in a rat and porcine model of myocardial infarction: Potential adjunctive therapy for percutaneous coronary intervention
Authors:	Yeh, KC;Lee, CJ;Song, JS;Wu, CH;Yeh, TK;Wu, SH;Hsieh, TC;Chen, YT;Tseng, HY;Huang, CL;Chen, CT;Jan, JJ;Chou, MC;Shia, KS;Chiang, KH
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	CXCR4 antagonists have been claimed to reduce mortality after myocardial infarction in myocardial infarction (MI) animals, presumably due to suppressing inflammatory responses caused by myocardial ischemia-reperfusion injury, thus, subsequently facilitating tissue repair and cardiac function recovery. This study aims to determine whether a newly designed CXCR4 antagonist DBPR807 could exert better vascular-protective effects than other clinical counterparts (e.g., AMD3100) to alleviate cardiac damage further exacerbated by reperfusion. Consequently, we find that instead of traditional continuous treatment or multiple-dose treatment at different intervals of time, a single-dose treatment of DBPR807 before reperfusion in MI animals could attenuate inflammation via protecting oxidative stress damage and preserve vascular/capillary density and integrity via mobilizing endothelial progenitor cells, leading to a desirable fibrosis reduction and recovery of cardiac function, as evaluated with the LVEF (left ventricular ejection fraction) in infarcted hearts in rats and mini-pigs, respectively. Thus, it is highly suggested that CXCR4 antagonists should be given at a single high dose prior to reperfusion to provide the maximal cardiac functional improvement. Based on its favorable efficacy and safety profiles indicated in tested animals, DBPR807 has a great potential to serve as an adjunctive medicine for percutaneous coronary intervention (PCI) therapies in acute MI patients.
Date:	2022-10-03
Relation:	International Journal of Molecular Sciences. 2022 Oct 3;23(19):Article number 11730.
Link to:	http://dx.doi.org/10.3390/ijms231911730
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1422-0067&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000867748800001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85139812696
Appears in Collections:	[Kak-Shan Shia] Periodical Articles [Chiung-Tong Chen] Periodical Articles [Teng-Kuang Yeh] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI000867748800001.pdf		3961Kb	Adobe PDF	166	View/Open

Loading...